Aflibercept 8 mg first to attain sustained imaginative and prescient positive aspects with greater than 70% of sufferers prolonged to intervals between 16 and 24 weeks in moist age-related macular degeneration at two years

10

August

2023

Abstract

Outcomes from PULSAR display long run efficacy of aflibercept 8 mg with prolonged dosing intervals reaching as much as 24 weeks and imaginative and prescient enhancements akin to Eylea™ (aflibercept 2 mg) at mounted 8-weekly dosing over two years / Sufferers randomized at baseline to aflibercept 8 mg 16-week dosing routine obtained a imply of 8.2 injections (4.6 fewer than Eylea (aflibercept 2 mg)) over two years / Security profile of aflibercept 8 mg in neovascular (moist) age-related macular degeneration (nAMD) stays akin to Eylea (aflibercept 2 mg) with no new alerts recognized